“We’re in an era of more personalized or precision medicine, and the ability to target cancer treatment to a patient’s specific genetic mutation or biomarker is becoming the standard,” according to Richard Pazdur, MD.
Overcoming challenges of medical therapy starts with leveraging guidelines.
Researchers studying a novel multimodal analgesia protocol at multiple institutions in the U.S. for patients having penile implant surgery found narcotic prescriptions before, during, and in the post-surgery recovery period fell from as high as 50 to 60 narcotic pills to 10 to 15 pills.
Two pharmaceuticals in late-stage development may offer new therapeutic options for patients with rare forms of hyperoxaluria.
“I think [MRI-guided transurethral ultrasound ablation] is a potentially great option for patients who opt for either whole- or partial-gland treatment,” says researcher Steven S. Raman, MD.
Myovant Sciences recently announced positive phase III trial results for its once-daily oral small molecule gonadotropin-releasing hormone antagonist relugolix, for the treatment of advanced prostate cancer.
Urologists, oncologists, and prostate cancer patients are entering a new era in prostate cancer therapy—one that is going to be genetically defined.
Guideline-directed care often leads to better outcomes, but that’s not the case with the AUA’s antibiotic prophylaxis guidelines for diabetic patients undergoing primary penile prosthesis implantation. Authors of an ongoing study have found that adhering to the antibiotic prophylaxis guidelines results in a five-fold increased infection risk among diabetic penile prothesis patients, greatly increasing their risk for explantation.
Newly diagnosed low- and high-risk prostate cancer patients seen during the same appointment by a urologist and radiation oncologist were more likely than patients in a nationwide cohort to choose evidence-based care, according to a recent study.
“There is now sufficient data to support the use of prostate MRI in all men before their initial prostate biopsy when the MRI is of sufficient quality,” says policy statement co-author Marc A. Bjurlin, DO, MSc.